Lack of beneficial effect of COX-2 inhibitors in an experimental
model of colitis

Ca, Lesch; Er, Kraus; Sánchez, Belén Sabio; Gilbertsen, Richard B.; Guglietta, Antonio

doi:10.1358/mf.1999.21.2.529236

Cited by 41 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, it has been found that some COX-2 inhibitors did no exert any beneficial effect in an experimental model of colitis and could exacerbate the inflammationassociated colonic injury [9,10]. In contrast, others investigators including our research group demonstrated that COX-2 inhibitors had a beneficial effect on experimental colitis in rats [7, 11 -16].…”

Section: Introductionmentioning

confidence: 83%

The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice

2005

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 83%

The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice

2005

View full text Add to dashboard Cite

show abstract

“…COX-2 inhibitors induced greater mortality than standard NSAIDs in the colitic animals, indicating that inhibition of COX-2 may have been the underlying cause of the exacerbation of injury and mortality [66]. Despite their potent extraintestinal anti-inflammatory activity, they had no beneficial effect in trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis [67].…”

Section: Coxibsmentioning

confidence: 99%

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

Kefalakes

Stylianides

Amanakis

et al. 2009

Eur J Clin Pharmacol

115

View full text Add to dashboard Cite

Background Nonsteroidal anti-inflammatory drugs (NSAIDs), conventional and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely used medications for the treatment of various inflammatory conditions. There is strong evidence of a possible association between the use of these drugs and the relapse of inflammatory bowel diseases (IBD). Objective Our objective was to examine the literature regarding the exacerbation of IBD associated with the use of conventional NSAIDs and selective COX-2 inhibitors and the underlying pathogenetic mechanisms. Study design We reviewed articles, including original papers, controlled trials, case reports, reviews, and editorials published in English at the PubMed, Scopus Database, and Science Direct database, searching with the following keywords: nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, Coxibs, inflammatory bowel diseases (IBD), ulcerative colitis (UC), Crohn's disease (CD). Results There is substantial evidence that exacerbation of IBD happens after treatment with NSAIDs, but the available data remain conflicting, and it is not clear whether selective COX-2 inhibitors are safer than traditional NSAIDs. However, there is some evidence that selective COX-2 inhibition and COX-1 inhibition (with low-dose aspirin) appear to be well-tolerated in the short term. Regarding the mechanisms of relapse, the reduction of prostaglandins appears to be the hallmark of the NSAIDs adverse effects. Conclusions Further randomized, double-blind, controlled trials should be performed to address this issue, and more in vitro studies to identify the pathways involved are required.

show abstract

“…Continued twice-daily administration of these compounds for one week resulted in perforation of the colon, leading to death in a substancial number of the animals. Lesch et al (1999) evaluated three highly selective COX-2 inhibitors (NS-398, SC-58125 and PD-138387) on TNBS-induced colitis and observed that these three compounds do not seem to have any beneficial effect in this model. Zhang et al (2004) showed that celecoxib resulted in exacerbation of inflammation-associated with colonic damage and even led to perforation, megacolon and death of the rats, with the mortality rate reaching 50%.…”

Section: Studymentioning

confidence: 99%

The Role of COX-2 Inhibitors on Experimental Colitis

Paiotti¹,

Neto²,

Ribeiro³

et al. 2012

Inflammatory Bowel Disease - Advances in Pathogenesis and Management

View full text Add to dashboard Cite

Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis

Cited by 41 publications

References 0 publications

The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice

The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice

Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?

The Role of COX-2 Inhibitors on Experimental Colitis

Contact Info

Product

Resources

About